相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD226 opposes TIGIT to disrupt Tregs in melanoma
Julien Fourcade et al.
JCI INSIGHT (2018)
Contribution of inhibitory receptor TIGIT to NK cell education
Yuke He et al.
JOURNAL OF AUTOIMMUNITY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155
Naomi Takahashi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors
Sandra Martinez-Canales et al.
PLOS ONE (2017)
Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types
Fiore Cattaruzza et al.
CANCER RESEARCH (2017)
Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma
Yousef Zakharia et al.
CANCER RESEARCH (2017)
Anti-Tigit induces T cell mediated anti-tumor immune response and combines with immune checkpoint inhibitors to enhance strong and long term anti-tumor immunity
Minu K. Srivastava et al.
CANCER RESEARCH (2017)
Antibody against TIGIT (T cell immunoreceptor with Ig and ITIM domains) induces anti-tumor immune response and generates long-term immune memory
Angie Inkyung Park et al.
CANCER RESEARCH (2017)
Discovery and characterization of novel antagonistic antibodies that bind with high affinity to human, cynomolgus, and murine TIGIT, an immune checkpoint receptor
Julia C. Piasecki et al.
CANCER RESEARCH (2017)
Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG
Ofer Levy et al.
CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Jeffrey R. Sachs et al.
CLINICAL CANCER RESEARCH (2016)
Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
Baofu Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Yaxian Kong et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Stephen J. Blake et al.
CLINICAL CANCER RESEARCH (2016)
Identification of CD112R as a novel checkpoint for human T cells
Yuwen Zhu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
Takashi Inozume et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location
Kosuke Mima et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Increased Soluble CD155 in the Serum of Cancer Patients
Akiko Iguchi-Manaka et al.
PLOS ONE (2016)
Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
Chamutal Gur et al.
IMMUNITY (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma
Kosuke Mima et al.
JAMA ONCOLOGY (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
T-Cell Ig and ITIM Domain Regulates Natural Killer Cell Activation in Murine Acute Viral Hepatitis
Jiacheng Bi et al.
HEPATOLOGY (2014)
Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
Nicole Joller et al.
IMMUNITY (2014)
T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
Man Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Christopher J. Chan et al.
NATURE IMMUNOLOGY (2014)
Increased CD112 Expression in Methylcholanthrene-Induced Tumors in CD155-Deficient Mice
Yoko Nagumo et al.
PLOS ONE (2014)
Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
S. Liu et al.
CELL DEATH AND DIFFERENTIATION (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
The TIGIT/CD226 Axis Regulates Human T Cell Function
Ester Lozano et al.
JOURNAL OF IMMUNOLOGY (2012)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Accelerated tumor growth in mice deficient in DNAM-1 receptor
Akiko Iguchi-Manaka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis
D Pende et al.
MOLECULAR IMMUNOLOGY (2005)
Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)
S Tahara-Hanaoka et al.
INTERNATIONAL IMMUNOLOGY (2004)
Cutting edge: CD96 (Tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)
A Fuchs et al.
JOURNAL OF IMMUNOLOGY (2004)
Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule
C Bottino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
Overexpression of the CD155 gene in human colorectal carcinoma
D Masson et al.
GUT (2001)
分享论文
